Literature DB >> 23842708

Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome.

Esther Zipperer1, Jochen G Post, Matthias Herkert, Andrea Kündgen, Frank Fox, Rainer Haas, Norbert Gattermann, Ulrich Germing.   

Abstract

Patients with myelodysplastic syndromes (MDS) often show elevated serum ferritin levels at diagnosis, probably caused by increased intestinal iron uptake attributable to ineffective erythropoiesis. Many patients also develop transfusional iron overload. Hepcidin, a pivotal regulator of iron homeostasis, controls iron uptake in the duodenum as well as iron release from macrophages and is potentially involved in iron distribution to different organs. We measured serum hepcidin, together with other laboratory parameters related to iron metabolism and hematopoiesis (ferritin, transferrin, transferrin saturation, soluble transferrin receptor, erythropoietin, and hemoglobin), and C-reactive protein as marker of inflammation, in 89 MDS patients. Hepcidin levels were measured with two different competitive ELISAs: (a) EIA-4705 as described by Schwarz et al. (J Gastroenterol 46:648-656; 2011) and (b) Hepcidin 25 bioactive ELISA (EIA-5258), which was develop by DRG Diagnostics, Marburg, in 2012. Median hepcidin levels with EIA-5258 were as follows: entire cohort 17.5 ng/ml (n = 89), RA/RARS 5.9 ng/ml (n = 5), RCMD 17.8 ng/ml (n = 38), RS-RCMD 8.7 ng/ml (n = 7), RAEB I/II 29.1 ng/ml (n = 22), CMML I/II 16.9 ng/ml (n = 10), and MDS with del(5q) 26.3 ng/ml (n = 7). Hepcidin levels of the RA/RARS patients were significantly lower than in the other groups except RS-RCMD. RS-RCMD had significantly lower levels than RAEB and 5q- patients. There was a positive correlation between hepcidin levels and serum ferritin and transferrin saturation, and a negative correlation between hepcidin and hemoglobin and transferrin. Malcovati et al. (Blood 112:2676a, 2008), Santini et al. (PLoS One 6:e23109, 2011), and Ambaglio et al. (Haematologica 98:420-423, 2013), using mass spectrometry, reported similar results. We further assessed transfusional status and could show that patients who had been transfused have significantly higher hepcidin levels (median 33.3 versus 8.8 ng/ml (p < 0.001)). A dichotomized hepcidin level correlated with worse survival. EIA-4705 as described by Schwarz showed no correlation with markers of iron metabolism. Measurement of serum hepcidin with an improved ELISA yield results that correlate with other parameters of iron metabolism as well as survival and transfusion needs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23842708     DOI: 10.1007/s00277-013-1839-5

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  9 in total

1.  Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anemia.

Authors:  Gianluca Abbati; Federica Incerti; Chiara Boarini; Francesca Pileri; Davide Bocchi; Paolo Ventura; Elena Buzzetti; Antonello Pietrangelo
Journal:  Intern Emerg Med       Date:  2018-11-29       Impact factor: 3.397

2.  Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes.

Authors:  Hiroshi Kawabata; Kensuke Usuki; Maki Shindo-Ueda; Junya Kanda; Kaoru Tohyama; Akira Matsuda; Kayano Araseki; Tomoko Hata; Takahiro Suzuki; Hidekazu Kayano; Kei Shimbo; Shigeru Chiba; Takayuki Ishikawa; Nobuyoshi Arima; Masaharu Nohgawa; Yasushi Miyazaki; Mineo Kurokawa; Shunya Arai; Kinuko Mitani; Akifumi Takaori-Kondo
Journal:  Int J Hematol       Date:  2019-07-29       Impact factor: 2.490

3.  The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study.

Authors:  Antonio Macciò; Clelia Madeddu; Giulia Gramignano; Carlo Mulas; Luciana Tanca; Maria Cristina Cherchi; Carlo Floris; Itaru Omoto; Antonio Barracca; Tomas Ganz
Journal:  Haematologica       Date:  2014-09-19       Impact factor: 9.941

4.  Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions.

Authors:  Rui Cui; Robert Peter Gale; Guoqing Zhu; Zefeng Xu; Tiejun Qin; Yue Zhang; Gang Huang; Bing Li; Liwei Fang; Hongli Zhang; Lijuan Pan; Naibo Hu; Shiqiang Qu; Zhijian Xiao
Journal:  Leuk Res       Date:  2014-02-10       Impact factor: 3.156

5.  Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes.

Authors:  Louise de Swart; Chloé Reiniers; Timothy Bagguley; Corine van Marrewijk; David Bowen; Eva Hellström-Lindberg; Aurelia Tatic; Argiris Symeonidis; Gerwin Huls; Jaroslav Cermak; Arjan A van de Loosdrecht; Hege Garelius; Dominic Culligan; Mac Macheta; Michail Spanoudakis; Panagiotis Panagiotidis; Marta Krejci; Nicole Blijlevens; Saskia Langemeijer; Jackie Droste; Dorine W Swinkels; Alex Smith; Theo de Witte
Journal:  Haematologica       Date:  2017-11-09       Impact factor: 9.941

6.  Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes.

Authors:  Louise de Swart; Simon Crouch; Marlijn Hoeks; Alex Smith; Saskia Langemeijer; Pierre Fenaux; Argiris Symeonidis; Jaroslav Cermâk; Eva Hellström-Lindberg; Reinhard Stauder; Guillermo Sanz; Moshe Mittelman; Mette Skov Holm; Luca Malcovati; Krzysztof Mądry; Ulrich Germing; Aurelia Tatic; Aleksandar Savic; Antonio Medina Almeida; Njetocka Gredelj-Simec; Agnes Guerci-Bresler; Odile Beyne-Rauzy; Dominic Culligan; Ioannis Kotsianidis; Raphael Itzykson; Corine van Marrewijk; Nicole Blijlevens; David Bowen; Theo de Witte
Journal:  Haematologica       Date:  2019-06-06       Impact factor: 9.941

7.  Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes.

Authors:  Sotirios G Papageorgiou; Ioannis Kotsianidis; Anthi Bouchla; Argyris Symeonidis; Athanasios Galanopoulos; Nora-Athina Viniou; Eleftheria Hatzimichael; Theodoros P Vassilakopoulos; Dimitrios Gogos; Aikaterini Megalakaki; Panagiotis Zikos; Panagiotis Diamantopoulos; Alexandra Kourakli; Panagiota Giannoulia; Menelaos Papoutselis; Elias Poulakidas; Maria Arapaki; Anna Vardi; Achilles Anagnostopoulos; Despoina Mparmparousi; Maria Papaioannou; Eleni Bouronikou; Maria Dimou; Helen Papadaki; Panayiotis Panayiotidis; Vasiliki Pappa
Journal:  Ther Adv Hematol       Date:  2020-12-08

Review 8.  The Interplay between Drivers of Erythropoiesis and Iron Homeostasis in Rare Hereditary Anemias: Tipping the Balance.

Authors:  Simon Grootendorst; Jonathan de Wilde; Birgit van Dooijeweert; Annelies van Vuren; Wouter van Solinge; Roger Schutgens; Richard van Wijk; Marije Bartels
Journal:  Int J Mol Sci       Date:  2021-02-23       Impact factor: 5.923

9.  Correlation of hepcidin and serum ferritin levels in thalassemia patients at Chiang Mai University Hospital.

Authors:  Adisak Tantiworawit; Sujaree Khemakapasiddhi; Thanawat Rattanathammethee; Sasinee Hantrakool; Chatree Chai-Adisaksopha; Ekarat Rattarittamrong; Lalita Norasetthada; Pimlak Charoenkwan; Somdet Srichairatanakool; Kanda Fanhchaksai
Journal:  Biosci Rep       Date:  2021-02-26       Impact factor: 3.840

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.